A medical device maker moves past a cyber scare
- Stryker is a global medical technology company serving more than 150 million patients a year.
- Q2 2026 organic sales grew 9 percent, confirming that a Q1 cybersecurity incident was a temporary disruption.
- Management raised the lower end of full-year organic sales guidance to a range of 8.3 percent to 9.3 percent.
- A new supply chain issue in the peripheral vascular business caused severe backorders and a 6.7 percent drop in U.S. Vascular sales.
- Finn sees a balanced picture, with strong core demand offset by occasional execution missteps.
Bouncing back from a cyber shock
Stryker had a difficult start to 2026 when a March cybersecurity incident disrupted production and operations. Investors worried that the company might lose permanent market share. The Q2 results put those fears to rest. Organic sales rebounded with 9 percent growth, and management raised the bottom end of its full-year guidance.
The bull case focuses on this strong underlying demand. Hospitals still need joint replacements, surgical tools, and emergency equipment. The Mako robotic surgery system just posted its best second quarter for installations ever. The quick recovery from the cyber event shows that hospital customers remain loyal to Stryker products.
The bear case points to a new operational hiccup. Stryker suffered a supply disruption at an Inari peripheral vascular plant in Q2, which pushed U.S. Vascular sales down 6.7 percent year over year. If management cannot resolve this backorder issue by the end of Q3 as promised, competitors might step in to take share in a highly competitive market.
The next twelve months depend on clean execution. Stryker needs to clear the vascular backorders, successfully roll out new products like Mako RPS, and avoid any more production surprises.
Hospitals buy the tools and implants
Stryker makes money by selling medical devices and services to doctors, hospitals, and other healthcare facilities. Its products help in surgery, patient handling, emergency care, stroke treatment, joint replacement, trauma care, and spine therapies.
This is usually a steady kind of business. Many products are tied to necessary medical care rather than impulse spending. Stryker also benefits from a wide product catalog and long sales relationships with hospitals.
The weak spot is execution. A hospital can like Stryker products and still switch when supplies are late or systems go offline. The recent cyber incident and the vascular supply disruption show that even a leading medical device company can lose sales when its production stops working.
The product bag
Instruments
This includes surgical equipment and navigation systems used in operating rooms. It is part of the MedSurg and Neurotechnology segment.
Endoscopy
Endoscopy includes camera, scope, and communications systems that help doctors see and work inside the body during procedures.
Medical
This group includes patient handling, emergency medical equipment, and related hospital products. Demand is tied to daily hospital and emergency care needs.
Vascular
Vascular includes minimally invasive products for acute ischemic and hemorrhagic stroke and venous thromboembolism. It includes the Inari Medical acquisition.
Hip and knee implants
Stryker sells implants used in joint replacement surgery. This is a core part of Orthopaedics and depends on procedure volume and surgeon preference.
Trauma, extremities, and spine therapies
These products support trauma, extremity, spinal injury, deformity, and degenerative care.
Ortho Tech and Mako
This combines orthopaedic instruments with Mako and enabling technologies, making robotic surgery easier for customers to adopt.
Two big engines
Segment mix is estimated based on historical splits. Both MedSurg and Neurotechnology and Orthopaedics rebounded strongly in Q2 2026.
What could break the case
Vascular supply backorders linger
High impact · Medium oddsA supply disruption in the Inari peripheral vascular business caused a severe backorder and lost sales in Q2 2026. If this is not resolved by Q3, customers might permanently shift to competitors in this fast-moving market.
Cyber event margin hangover
Medium impact · Medium oddsThe March 2026 cyber incident is mostly in the past, but the company may still face ongoing remediation and security upgrade costs. These expenses could pressure second-half operating margins.
Regulation and pricing pressure
Medium impact · High oddsStryker sells globally and faces heavy medical device regulation. Hospitals and governments also push to control healthcare costs. These forces can slow product launches or pressure prices.
In one breath
What does Stryker actually sell?
Stryker sells medical technology used by hospitals and doctors. Its main areas include surgical equipment, endoscopy systems, emergency and patient handling products, vascular tools, joint implants, and trauma products.
Did the cybersecurity incident permanently hurt sales?
It appears the damage was temporary. Organic sales bounced back with 9 percent growth in Q2 2026, and management raised the bottom end of its full-year guidance.
What is going on with the vascular business?
The U.S. Vascular business saw sales decline 6.7 percent in Q2 2026 due to a supply disruption at an Inari plant. Management expects the backorder to clear up by the end of the third quarter.
